FDAnews
www.fdanews.com/articles/96835-israeli-pharmaceutical-start-up-dermipsor-publishes-phase-ii-results

Israeli Pharmaceutical Start-Up DermiPsor Publishes Phase II Results

August 7, 2007

According to Israeli newspaper Globes, Meytag Technology Incubator’s portfolio company DermiPsor has obtained the results of a Phase II clinical trial for its psoriasis drug.

The Meytag Technology Incubator is a nonprofit, government-sponsored technology R&D center in Israel.

Globes reported that the company had positive indications for its preparation, which includes derivatives of Vitamin B and Vitamin D, over three test groups.

The trial showed improvement in the condition of patients who used DermiPsor’s preparation compared with the other groups, the paper added.

Alice Gotlieb and Mark Lebwohl, two members of DermiPsor’s scientific advisory board, said that the study results were enough to continue to Phase III trials.